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CONCISE COMMUNICATION
Adverse events of raltegravir and
dolutegravir
Luigia Elzia,M, Stefan Erbb,M, Hansjakob Furrerc, Matthias Cavassinid,
Alexandra Calmye, Pietro Vernazzaf, Huldrych Gu¨nthardg,h,
Enos Bernasconii, Manuel Battegayb, for the Swiss HIV
Cohort Study Group
Objective: To compare the frequency and risk factors of toxicity-related treatment
discontinuations between raltegravir and dolutegravir.
Design: Prospective cohort study.
Methods: All antiretroviral therapy (ART)-naı¨ve and ART-experienced HIV-infected
individuals from the Swiss HIV Cohort Study who initiated raltegravir or dolutegravir
between 2006 and 2015 were investigated concerning treatment modification within
the first year.
Results: Of 4041 patients initiating ART containing raltegravir (n¼2091) or dolute-
gravir (n¼1950), 568 patients discontinued ART during the first year, corresponding to
a rate of 15.5 [95% confidence interval (CI) 14.5–16.9] discontinuations per 100
patient-years. Only 10 patients on raltegravir (0.5%) and two patients on dolutegravir
(0.1%) demonstrated virologic failure. The main reason for ART discontinuation was
convenience expressed as patient’s wish, physician’s decision, or treatment simplifica-
tion (n¼302). Toxicity occurred in 4.3% of patients treated with raltegravir and 3.6%
with dolutegravir, respectively. In multivariable analysis, the only independent risk
factor for discontinuing ART because of toxicity was female sex (hazard ratio 1.98, 95%
CI 1.45–2.71, P<0.001).
Neuropsychiatric complaints were the most commonly reported toxic adverse events
and more frequent in the dolutegravir (n¼33, 1.7%) compared with the raltegravir
group (n¼13, 0.6%). Risk of discontinuation for neurotoxicity was lower for raltegravir
than for dolutegravir in multivariable analysis (hazard ratio 0.46, 95% CI 0.22–0.96,
P¼0.037).
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Conclusion: In this, large cohort raltegravir and dolutegravir-containing regimen
demonstrated a high virologic efficacy. Drug toxicity was infrequent and discontinua-
tion because of neuropsychiatric events within the first year of treatment was only
marginal higher with dolutegravir compared with raltegravir. However, monitoring of
neurotoxic side-effects of dolutegravir is important.
Copyright  2017 The Author(s). Published by Wolters Kluwer Health, Inc.
AIDS 2017, 31:1853–1858
Keywords: dolutegravir, HIV, neuropsychiatric adverse events, raltegravir,
toxicity
Introduction
Raltegravir and dolutegravir are currently among the
most commonly used integrase strand transfer inhibitors
(INSTI), which are part of preferred antiretroviral therapy
(ART) regimens according to various guideline boards
such as the International AIDS Society and the European
AIDSClinical Society [1,2]. Both agents show a very high
antiretroviral potency and, in particular for dolutegravir, a
very low risk of virologic failure and development of
drug-associated resistance. Further beneficial character-
istics of both INSTIs are the excellent tolerability, the low
interaction potential as well as the excellent penetration
into the central nervous system [3,4,5,6]. No specific
organ toxicity associated with raltegravir and dolutegravir
was identified in randomized clinical trials. Owing to
these favorable characteristics, the once-daily administra-
tion, and the low dosage allowing for fixed-dosed
combination, the use of dolutegravir in the treatment of
HIV-infected patients has rapidly increased since the
approval in 2013.
However, recent reports, mainly from retrospective data
and smaller cohorts, raised concerns about the safety of
dolutegravir in real-life settings with higher than
expected discontinuation rates, particularly in respect
of neuropsychiatric adverse events [7–9,10].
The aim of our study was to compare the frequency and
risk factors of discontinuation between dolutegravir and
raltegravir because of any reason and more specifically
because of toxicity adverse events in a large cohort of
HIV-infected individuals.
Methods
Study setting
We analysed the Swiss HIV Cohort Study (SHCS)
database, a large prospective and ongoing cohort study in
Switzerland with continuous enrolment of HIV-infected
individuals of 16 years or older. In the SHCS, basic
sociodemographic characteristics, clinical course, ART,
reasons for discontinuation or change of the ARTregime,
comedication, immunological, and virological data as
well as information on comorbidity and coinfections are
collected at registration into the study and every 6 months
thereafter on standardized protocols. For the present
analysis we used SHCS database update of January 2017.
Study population
All HIV-infected individuals participating in the SHCS
starting an antiretroviral regime containing raltegravir or
dolutegravir combined with appropriate backbone
between 1 April 2006 and 31 December 2015 and
who had a follow-up of at least 12 months were eligible
for this study.
Definitions
Treatment modification was defined as discontinuation or
switch of ART within the first year of treatment.
Discontinuation was defined as stopping dolutegravir or
raltegravir for at least 4 weeks. A switch to another
regimen was defined as changing one or more drugs
within 4 weeks after stopping ART. The main reason for
treatment modification was classified as treatment failure,
intolerance, and/or toxic effects, the patient’s choice, the
physician’s decision, and other reasons. Since 2014 more
detailed reasons for drug discontinuation were introduced
and prospectively collected in the SHCS database,
including treatment simplification, concerns about drug
interactions and adherence. Toxicity, predominantly from
the nervous system was specifically coded detailed as
neuropsychiatric toxicity, headache, or peripheral neuro-
pathy.
Statistical analysis
The primary endpoint was the time to first treatment
modification (i.e., switch to another antiretroviral regime
or discontinuation) during the first year of treatment.
Basic sociodemographic characteristics, CD4þ cell
counts, HIV RNA, and ART were compared using
the x2 test for categorical and Mann–Whitney U or
Kruskal–Wallis test for continuous variables. We used
Kaplan–Meier curves to describe the cumulative inci-
dence of treatment modification according to either
raltegravir or dolutegravir-containing ART regimen, and
the curves were compared using log-rank tests. Uni and
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multivariable Cox regression analysis was used to
investigate risk factors for treatment modification because
of any reason and because of adverse events. The
following variables were assessed: sex, age, ethnicity, prior
AIDS-defining condition, hepatitis C virus coinfection,
CD4þ cell count, HIV RNA, treatment status, ART
backbone (abacavir–lamivudine versus tenofovir–emtri-
citabine versus other) and INSTI (raltegravir versus
dolutegravir).
All patients were censored at 1 year after starting ART if
no treatment modification or death had occurred. P
values< 0.05 were considered statistically significant. All
analyses were performed using commercially available
software (STATA, version 13.1 for Windows, StataCorp,
College Station, Texas, USA).
Results
During the study period from 1 April 2006 to 31
December 2015, 4041 HIV-infected individuals partici-
pating in the SHCS started an antiretroviral regimen
containing either raltegravir (n¼ 2091) or dolutegravir
(n¼ 1950). Baseline characteristics are shown in Table 1.
Dolutegravir was mostly combined with abacavir–
lamivudine in a single-tablet regimen in comparison
with raltegravir being most often combined with
tenofovir–emtricitabine.
Of 4041 patients included in this study, 568 (14.1%)
patients had modification of their ART because of
any reason during the first year of treatment, correspond-
ing to 15.5 [95% confidence interval (CI) 14.5–16.9]
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Table 1. Baseline characteristics of the study population with raltegravir and dolutegravir containing antiretroviral regimen (nU4041) and
reasons for treatment modification.
Raltegravir N¼2091 Dolutegravir N¼1950
n % n % P value
Male 1474 70.5 1455 74.6 0.003
Age, median (IQR) 48 41–54 48 40–54 0.447
White ethnicity 1752 83.8 1566 80.3 0.004
Risk
MSM 887 42.4 997 51.1
Heterosexual 723 34.6 679 34.8 <0.001
PWID 245 11.7 107 5.5
Other 236 11.3 167 8.6
Prior AIDS-defining condition 623 29.8 381 19.5 <0.001
HCV coinfection 641 30.7 377 19.3 0.001
CD4þ cells per ml
<350 713 34.1 341 17.5 <0.001
350–500 481 23.0 421 21.6
>500 897 42.9 1188 60.9
HIV RNA >100000 copies per ml 574 42.8 608 39.4 0.069
Treatment-naive 188 9.0 327 16.8 <0.001
Backbone
Abacavir–lamivudine 302 14.5 1149 59.1 <0.001
Tenofovir–emtricitabine 955 45.7 586 30.1
Other 833 39.9 209 10.8
Treatment modification 364 17.4 204 10.5 <0.0001
Treatment failure 10 0.48 2 0.10 0.028
Toxicity
Total 106 5.07 75 3.85 0.060
Gastrointestinal 6 0.29 19 0.97 0.005
Liver 2 0.10 7 0.36 0.098
Lipids 12 0.57 1 0.05 0.003
Neuropsychiatric 13 0.62 33 1.69 0.001
Kidney 3 0.14 0 0.00 0.251
Hematologic 9 0.43 2 0.10 0.046
Allergy 16 0.77 4 0.21 0.011
IRIS 6 0.29 1 0.05 0.076
Other 39 1.87 8 0.41 <0.0001
Convenience
Total 210 10.04 92 4.72 <0.0001
Patient’s wish 54 2.58 44 2.26 0.502
Physician’s decision 94 4.50 26 1.33 <0.0001
Treatment simplification 62 2.97 22 1.13 <0.0001
Pregnancy 3 0.14 11 0.56 0.023
Other 25 2.97 18 1.13 0.399
No information 10 0.48 6 0.31 0.390
IQR, interquartile range; IRIS, immune reconstitution inflammatory syndrome; PWID, people who inject drugs.
discontinuations per 100 patient-years. Among them, 364
(17.4%) patients were treated with raltegravir and 204
(10.5%) with dolutegravir (Table 1).
The main reason for treatment modification was
convenience (n¼ 302) expressed by the patient’s wish,
physician’s decision or treatment simplification, followed
by toxicity or intolerance (n¼ 181). Only 10 patients
under raltegravir (0.48%) and two patients under
dolutegravir (0.10%) demonstrated virological failure
(Table 1).
In multivariable analysis, risk factors of ART modifica-
tion within the first year of treatment regardless of the
main reason were female sex (hazard ratio 1.28, 95% CI
1.06–1.53, P¼ 0.009), younger age (hazard ratio 0.90,
95% CI 0.83–0.98 per 10 years older, P¼ 0.011), HIV
RNAmore than 100 000 copies per ml at baseline (hazard
ratio 1.49, 95% CI 1.09–2.02, P¼ 0.011), and starting a
raltegravir-containing regime (hazard ratio 1.71, 95% CI
1.38–2.08, P< 0.001; S1 Table. Supplementary material,
http://links.lww.com/QAD/B135). Among pregnant
women, those treated with dolutegravir were more likely
to discontinue ART compared with those treated with
raltegravir. However, this difference was not statistically
significant (P¼ 0.205).
Adverse events leading to ART modification within the
first year occurred in 4.5% of the patients, corresponding
to a discontinuation rate of 4.4 (95% CI 3.6–5.5) per 100
patient-years for dolutegravir and 5.7 (95% 4.7–6.9) per
100 patient-years for raltegravir. This difference did not
reach statistical significance (P¼ 0.11). In multivariate
analysis, the only independent risk factor for ART
modification because of toxicity was female sex (hazard
ratio 1.98, 95% CI 1.45–2.71, P< 0.001; Table 2).
Neuropsychiatric complaints, although observed in less
than 2% of the patients, were the most commonly
reported toxicity adverse events and more frequently in
the dolutegravir group [discontinuation rate of 1.83 (95%
CI 1.30–2.57) per 100 patient-years] compared with the
raltegravir group [discontinuation rate of 0.70 (95% CI
0.41–1.21) per 100 patient-years, P¼ 0.002]. In multi-
variable analysis of the subgroup with neurotoxicity, there
was a lower risk of discontinuation for raltegravir
compared with dolutegravir (hazard ratio 0.46, 95% CI
0.22–0.96, P¼ 0.037; S2 Table. supplementary material,
http://links.lww.com/QAD/B135).
Gastrointestinal adverse events were the second most
common reason for ART modification and reported in
19 dolutegravir-treated patients and only in six patients
under raltegravir. Allergies and lipid disorders as reason
for ART modification were more frequent in raltegravir
(16 and 12, respectively) than dolutegravir (four and one,
respectively) patients. There were only seven immune
reconstitution syndrome events after initiation of a
INSTI-containing regimen, six in the raltegravir group
and one in the dolutegravir group (P¼ 0.076) (Table 1).
Discussion
The large study, involving 4041 HIV-individuals who
have started a raltegravir or dolutegravir-containing ART
within the SHCS, illustrates in a real-life setting an overall
low rate of ART modification because of adverse events
or intolerance for both INSTIs (<5%). The rate of
neuropsychiatric adverse events was very low (<2%).
There were higher discontinuation rates of dolutegravir
(1.7%) compared with raltegravir (0.6%) because of
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Table 2. Risk factors of modification of an antiretroviral regimen containing raltegravir versus dolutegravir within the first year of treatment
because of toxicity or intolerance.
Univariate analysis Multivariate analysis
Variable HR 95% CI P value HRa 95% CI P value
Female 1.86 1.39–2.49 <0.001 1.98 1.45–2.71 <0.001
Age, per 10 years older 0.91 0.80–1.04 0.156 0.93 0.81–1.07 0.319
Nonwhite ethnicity 1.00 0.69–1.46 0.986 0.75 0.50–1.13 0.172
Prior AIDS-defining condition 0.86 0.61–1.22 0.405 0.89 0.56–1.41 0.513
HCV-coinfection 0.90 0.64–1.26 0.538 0.80 0.56–1.14 0.221
CD4þ cells per ml
<350 Reference Reference
350–500 0.89 0.58–1.35 0.573 0.98 0.63–1.49 0.880
>500 0.98 0.70–1.39 0.922 1.07 0.73–1.56 0.735
HIV RNA >100000 copies per ml 1.45 0.87–2.42 0.157 1.53 0.86–2.71 0.149
Treatment naive 1.07 0.70–1.64 0.739 1.05 0.64–1.70 0.858
Backbone
Abacavir–lamivudine Reference Reference
Tenofovir–emtricitabine 1.05 0.75–1.47 0.773 0.91 0.63–1.32 0.626
Other 1.07 0.74–1.55 0.701 0.97 0.64–1.49 0.902
Raltegravir versus dolutegravir 1.27 0.95–1.70 0.106 1.30 0.92–1.84 0.140
Hazard ratios in univariate and multivariate analysis. CI, confidence interval; HR, hazard ratio.
aadjusted for all variables listed.
neuropsychiatric adverse events. The only independent
risk factor of discontinuing a raltegravir or dolutegravir
containing ARTwithin the first year of treatment because
of adverse events was female sex. Importantly, we found
an outstanding drug potency with an extremely low rate
of treatment failures for both drugs (<0.5% of the
patients).
Our results are somewhat in contrast with those recently
reported in the literature [7–9], assigning clearly higher
rates of treatment discontinuation because of any adverse
events (7.6–13.7%) and neuropsychiatric adverse events
(5.6–9.9%) for dolutegravir. One explanation might be
the smaller number of patients included in those studies
which may contribute to an overestimation of the
neuropsychiatric adverse events of dolutegravir. In the
study by Hoffmann et al. [9], the rates of neuropsychiatric
adverse events leading to discontinuation within 12
months was estimated to be 5.6% for dolutegravir,
affecting mainly women and older patients, but only 0.7%
for elvitegravir and 1.9% for raltegravir. Results from a
Spanish cohort of 2021 HIV-infected individuals treated
with INSTIs showed a relatively low discontinuation rate
of dolutegravir because of neuropsychiatric complaints
(2.7 per 100 patient-years) as well, however, only in
patients with an abacavir–lamivudine backbone, but not
with tenofovir–emtricitabine [11]. In our study neither
sex, age, nor the backbone, was associated with
discontinuation of dolutegravir compared with raltegravir
because of toxicity of the central nervous system.
Very recent data from a North American cohort
including 2180 patients receiving dolutegravir and 917
raltegravir did not show an increased risk of psychiatric
disorders or ART discontinuations because of psychiatric
adverse events related to the use of dolutegravir, although
more patients treated with dolutegravir had a psychiatric
disease at baseline [12]. This might be explained by the
favorable profile of dolutegravir concerning the risk of
drug–drug interactions in patients treated with psychiat-
ric medications as well as the convenience of a one-pill
regimen in this particular patient population.
Interestingly, female patients in our study showed a higher
risk of INSTI discontinuation because of any toxicity
adverse event compared with male patients. If different
pharmacokinetics or lower body weight may have
contributed to higher rate of INSTI-related adverse
events in female patients remains hypothetical. Of note,
recently, a correlation between plasma concentration of
dolutegravir and neuropsychiatric side-effects was shown
in a small set of HIV-infected individuals [13].
The sequential introduction of raltegravir and dolute-
gravir could have impacted on the probability to
discontinue raltegravir when dolutegravir was available
as alternative ART compound since 2013. After 2013,
most patients started ART-containing dolutegravir
(n¼ 1944, 79%) compared with raltegravir (n¼ 516,
21%). However, we did not find any difference among
multivariate models of the probability to discontinue the
integrase inhibitor regardless of the main reason and
because of neuropsychiatric side-effects when analyses
were restricted to the time period before and after 2013.
Our study has some important limitations: information
bias might have occurred, as imprecise coding of the
reasons for discontinuation of the ART regime cannot
be excluded. However, in case of specific symptoms/
adverse effects, the proper reason is relatively easy to
capture. The reasons for discontinuation are collected by
predefined codes in the SHCS database; thus, more
detailed information are lacking. Precise descriptions of the
particular symptoms and data of minor side-effects not
leading to discontinuation of the ART are not available.
Therefore, the real burden of all neuropsychiatric events
(including minor events) might be underestimated. Only
toxicity data leading to the discontinuation of the ART
regime are collected in the SHCS database, which,
however, represents a highly valuable and representative
endpoint. The raltegravir and dolutegravir group differed
in some of the baseline characteristics. In addition, other
characteristics than those available in the SHCS could have
been associated with adverse events. We did not consider
data on adherence to treatment for our analysis, and, finally,
no data on plasma concentration of INSTI were available
for this study.
The main strengths are the large sample size of our study
population, the real-life setting, and the prospective
collection of patient data including reasons for ART
discontinuation.
In conclusion, our study confirms the excellent
tolerability of the INSTIs raltegravir and dolutegravir
in the treatment of HIV-infected individuals. Raltegravir
or dolutegravir drug toxicity is an infrequent reason for
treatment modification. Although neuropsychiatric
complaints are indeed observed more frequently in
patients on dolutegravir compared with raltegravir, in
overall these adverse events remain relatively rare. Patient
information and monitoring of adverse events are
important for early detection of neurotoxicity. In case
neuropsychiatric side-effects occur with dolutegravir, a
switch to an alternative INSTI remains a valuable option.
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